When did the Arcutis (ARQT) director’s 10,000-share sale occur?

The 10,000-share sale by Arcutis director Howard G. Welgus took place on April 1, 2026. It involved multiple trades between $23.61 and $24.12 per share, resulting in a weighted average sale price of $23.8801 for the reported transaction.

Planned sale: Arcutis (ARQT) director disposes of 10,000 shares

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Arcutis Biotherapeutics director Howard G. Welgus reported an open-market sale of 10,000 shares of Common Stock at a weighted average price of $23.8801 per share. After this transaction, he directly holds 39,744 shares of Arcutis common stock.

The sale on April 1, 2026 was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025, with a plan end date of May 29, 2026. The shares were sold in multiple trades at prices ranging from $23.61 to $24.12 per share.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($238,801)

Net Sell 1 txn

Insider Welgus Howard G.

Role Director

Sold 10,000 shs ($239K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$23.8801	$239K

Holdings After Transaction: Common Stock — 39,744 shares (Direct)

Footnotes (1)

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.61 to $24.12, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Key Figures

Shares sold: 10,000 shares Weighted average sale price: $23.8801 per share Shares held after transaction: 39,744 shares +3 more

6 metrics

Shares sold 10,000 shares Open-market sale by director on April 1, 2026

Weighted average sale price $23.8801 per share Common Stock transaction

Shares held after transaction 39,744 shares Directly owned by Howard G. Welgus

Sale price range $23.61–$24.12 per share Multiple trades comprising the 10,000-share sale

10b5-1 plan adoption date March 11, 2025 Pre-arranged trading plan for the insider

10b5-1 plan end date May 29, 2026 Scheduled end of trading plan

Key Terms

Rule 10b5-1 trading plan, open-market sale, weighted average sale price

3 terms

Rule 10b5-1 trading plan regulatory

"was effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price."

Form 4 Insider Transactions: What Each Field Means →

04/03/2026 - 05:46 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Welgus Howard G.

(Last)

(First)

(Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE

CALIFORNIA

91361

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/01/2026		S⁽¹⁾		10,000	D	$23.8801⁽²⁾	39,744	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.61 to $24.12, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

	/s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Arcutis Biotherapeutics (ARQT) report?

Arcutis Biotherapeutics reported that director Howard G. Welgus sold 10,000 shares of Common Stock in an open-market transaction at a weighted average price of $23.8801 per share, leaving him with 39,744 directly owned shares after the sale.

How many Arcutis (ARQT) shares does Howard G. Welgus hold after the sale?

Following the reported transaction, director Howard G. Welgus directly holds 39,744 shares of Arcutis Biotherapeutics Common Stock. This figure reflects his position after selling 10,000 shares in the open market at a weighted average price of $23.8801 per share.

Was the Arcutis (ARQT) insider sale made under a Rule 10b5-1 plan?

Yes. The sale was effected under a Rule 10b5-1 trading plan adopted by Howard G. Welgus on March 11, 2025. The plan has an end date of May 29, 2026, indicating the transaction was pre-planned rather than discretionary market timing.

What price range did the Arcutis (ARQT) insider sale cover?

The 10,000 Arcutis shares sold by director Howard G. Welgus were executed in multiple trades between $23.61 and $24.12 per share. The Form 4 reports a weighted average sale price of $23.8801 across all these individual transactions.